SABS SAB Biotherapeutics, Inc.
USHealthcareAs of 2026-08-17
Why SABS matters now
SAB Biotherapeutics, Inc. (SABS) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.77 with +1.89% on the session and $343.0M in market capitalization; recent performance reads 1-month +12.68% and YTD +6.95%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-18.9M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E 5.47 and FCF yield -139.1%.
The latest indexable market news headline is "SAB Biotherapeutics Q2 Earnings Call Highlights" from MarketBeat.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Kropotova Alexandra filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
5.47
PEG
0.02
P/B
0.94
P/S
0.00
EV/EBITDA
8.13
DCF Value
$0.04
FCF Yield
-139.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.3%
ROA
-0.2%
ROIC
-24.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-18.9M | $-0.35 |
| Q4 2025 | $0.00 | $-16.9M | $-0.81 |
| FY 2025 | $0.00 | $13.3M | $-0.79 |
| Q3 2025 | $0.00 | $45.4M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.33
Target (Median)
$10.00
Target Range
$7.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.55
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies built upon human antibodies. The company leverages sophisticated genetic engineering and antibody research to cultivate specialized transchromosomic bovine herds. These unique animals are engineered to generate fully human antibodies, which are then directed against a variety of specific ailments. This broad scope includes infectious diseases such as COVID-19 and influenza, various immune and autoimmune conditions like type 1 diabetes, and potential applications in organ transplantation and cancer treatment. Central to their strategy is the proprietary DiversitAb immunotherapy platform, which yields wholly human polyclonal antibodies, thereby circumventing the need for human donors. Key assets in their clinical pipeline feature SAB-185, a fully human polyclonal antibody therapeutic currently undergoing Phase III trials for COVID-19, and SAB-176, another fully human polyclonal antibody in development for the prevention or treatment of severe influenza. Additionally, their preclinical portfolio contains SAB-142, intended for autoimmune disorders such as type 1 diabetes and for managing organ transplant induction/rejection. Established in 2014, SAB Biotherapeutics is based in Sioux Falls, South Dakota.